

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣药業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

**SUPPLEMENTAL ANNOUNCEMENT IN RESPECT OF
MAJOR TRANSACTION IN RELATION TO
COOPERATIVE DEVELOPMENT OF THE SITE LOCATED
AT YULIN CITY, GUANGXI PROVINCE**

Reference is made to the announcement (the “**Announcement**”) of Consun Pharmaceutical Group Limited (the “**Company**”) dated 31 May 2019 of the major transaction in relation to the cooperative development of the site located at Yulin City, Guangxi Province, the PRC. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to provide further information in relation to the “Basic information of the Project Land” appeared on page 4 of the Announcement:

It is expected that both Parcel-2 and Parcel-3 will be subject to land expropriation by the Yulin Municipal Government of Guangxi Zhuang Autonomous Region of the PRC and be sold through the governmental procedure of bidding, auction and quotation regulated by applicable PRC laws and regulations.

The Company would like to supplement and clarify that the statement “within five days from the completion of the transfer registration of and the vacant possession delivery of Parcel-2 and Parcel-3 from Yulin Pharmaceutical to the Project Company,...” appeared in the first paragraph on page 5 of the Announcement, should read as “based on the development plan contemplated under the Development Project, it is intended that Parcel-2 and Parcel-3 will be acquired by the Project Company after the Disposal-2. Within five days from the completion of the transfer registration of and the vacant possession delivery of Parcel-2 and Parcel-3 to the Project Company,...” instead.

This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 12 July 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.